PMID- 35203444
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 2
DP  - 2022 Jan 22
TI  - Decreased SLC27A5 Suppresses Lipid Synthesis and Tyrosine Metabolism to Activate 
      the Cell Cycle in Hepatocellular Carcinoma.
LID - 10.3390/biomedicines10020234 [doi]
LID - 234
AB  - Tyrosine is an essential ketogenic and glycogenic amino acid for the human body, 
      which means that tyrosine is not only involved in protein metabolism, but also 
      participates in the metabolism of lipids and carbohydrates. The liver is an 
      important place for metabolism of lipids, carbohydrates, and proteins. The 
      metabolic process of biological macro-molecules is a basis for maintaining the 
      physiological activities of organisms, but the cross-linking mechanism of these 
      processes is still unclear. Here, we found that the tyrosine-metabolizing 
      enzymes, which were specifically and highly expressed in the liver, were 
      significantly down-regulated in hepatocellular carcinoma (HCC), and had a 
      correlation with a poor prognosis of HCC patients. Further analysis found that 
      the reduction of tyrosine metabolism would activate the cell cycle and promote 
      cell proliferation. In addition, we also found that the solute carrier family 27 
      member 5 (SLC27A5) regulates the expression of tyrosine-metabolizing enzymes 
      through nuclear factor erythroid 2-related factor 2 (NRF2). Therefore, the 
      SLC27A5 and tyrosine-metabolizing enzymes that we have identified coordinate 
      lipid and tyrosine metabolism, regulate the cell cycle, and are potential targets 
      for cancer treatment.
FAU - Wang, Jiyan
AU  - Wang J
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 
      300350, China.
FAU - Qiao, Yaya
AU  - Qiao Y
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 
      300350, China.
FAU - Sun, Huanran
AU  - Sun H
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 
      300350, China.
FAU - Chang, Hongkai
AU  - Chang H
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 
      300350, China.
FAU - Zhao, Huifang
AU  - Zhao H
AD  - School of Integrative Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin 301617, China.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - School of Integrative Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin 301617, China.
FAU - Shan, Changliang
AU  - Shan C
AUID- ORCID: 0000-0002-4906-1686
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 
      300350, China.
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, 
      Chinese Academy of Sciences, Shanghai 201203, China.
LA  - eng
GR  - 81973356, 81902826and 81672781/National Nature Science Foundation of China/
GR  - 3206054, 91923101, 63213082and 92122017/the Fundamental Research Funds for the 
      Central Universities of Nankai University/
GR  - SIMM2105KF-08/the State Key Laboratory of Drug Research/
GR  - 2018YFC2002000/the National Key R&D Program of China/
PT  - Journal Article
DEP - 20220122
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC8869743
OTO - NOTNLM
OT  - cell cycle
OT  - hepatocellular carcinoma
OT  - lipids synthesis
OT  - solute carrier family 27 member 5 (SLC27A5)
OT  - tyrosine metabolism
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/01/22
CRDT- 2022/02/25 01:01
PHST- 2022/01/11 00:00 [received]
PHST- 2022/01/17 00:00 [revised]
PHST- 2022/01/19 00:00 [accepted]
PHST- 2022/02/25 01:01 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/01/22 00:00 [pmc-release]
AID - biomedicines10020234 [pii]
AID - biomedicines-10-00234 [pii]
AID - 10.3390/biomedicines10020234 [doi]
PST - epublish
SO  - Biomedicines. 2022 Jan 22;10(2):234. doi: 10.3390/biomedicines10020234.